Suppr超能文献

上尿路尿路上皮癌中程序性死亡蛋白 1 配体 1 表达升高与肿瘤进展相关,且与肿瘤浸润淋巴细胞密度增加相关。

Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.

机构信息

Department of Urology, Dokkyo Medical University, 880 Kitakobayashi Mibu, Utsunomiya, Tochigi, 321-0293, Japan.

Department of Urology, Utsunomiya Memorial Hospital, Utsunomiya, Tochigi, Japan.

出版信息

Cancer Immunol Immunother. 2020 May;69(5):689-702. doi: 10.1007/s00262-020-02499-7. Epub 2020 Feb 6.

Abstract

BACKGROUND

Increased expression of programmed cell death 1 ligand 1 (PD-L1) by tumor cells is thought to be a mechanism through which solid cancers promote immune tolerance. However, the association between PD-L1 expression and the prognosis of upper urinary tract urothelial carcinoma (UTUC) remains unknown.

METHODS

We examined immunohistochemical PD-L1 expression and the tumor-infiltrating lymphocyte density (TILD) in 79 patients with UTUC who underwent nephroureterectomy. We classified the tumors into four types based on the combination of PD-L1 expression and TILD, and studied the clinicopathological characteristics of these four tumor types.

RESULTS

Elevated expression of PD-L1 by tumor cells and a higher TILD were associated with a worse histological grade, higher pT stage, and higher peripheral blood neutrophil-to-lymphocyte ratio. Elevated expression of PD-L1 by tumor cells, a higher TILD, and type I, III, or IV tumors with elevated expression of either PD-L1 or TILD showed a positive correlation with poorer differentiation and local invasion. These three variables were associated with shorter progression-free survival and overall survival in univariate analysis, but only the latter was an independent determinant according to multivariate analysis. The patients who had type II tumors with lower PD-L1 expression and a lower TILD showed more favorable survival than the other three groups.

CONCLUSIONS

These findings suggest that PD-L1 expression and TILs in the tumor microenvironment influence the progression of UTUC. Accordingly, it is important to understand the immunologic characteristics of the tumor microenvironment to develop more effective treatment strategies for this cancer.

摘要

背景

肿瘤细胞程序性死亡配体 1(PD-L1)的表达增加被认为是实体瘤促进免疫耐受的一种机制。然而,PD-L1 表达与上尿路上皮癌(UTUC)预后之间的关系尚不清楚。

方法

我们对 79 例行肾输尿管切除术的 UTUC 患者的免疫组化 PD-L1 表达和肿瘤浸润淋巴细胞密度(TILD)进行了检测。我们根据 PD-L1 表达和 TILD 的组合将肿瘤分为四种类型,并研究了这四种肿瘤类型的临床病理特征。

结果

肿瘤细胞 PD-L1 表达升高和 TILD 升高与组织学分级较高、pT 分期较高和外周血中性粒细胞与淋巴细胞比值较高相关。肿瘤细胞 PD-L1 表达升高、TILD 升高以及Ⅰ型、Ⅲ型或Ⅳ型肿瘤(PD-L1 或 TILD 表达升高)与分化不良和局部侵犯呈正相关。这些三个变量在单因素分析中与无进展生存期和总生存期较短相关,但只有后者在多因素分析中是独立的决定因素。PD-L1 表达较低且 TILD 较低的Ⅱ型肿瘤患者的生存情况优于其他三组。

结论

这些发现表明 PD-L1 表达和肿瘤微环境中的 TIL 影响 UTUC 的进展。因此,了解肿瘤微环境的免疫特征对于开发这种癌症的更有效治疗策略很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/11027817/62c2bec83df7/262_2020_2499_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验